exemestane,tamoxifen,triptorelin
azurity pharmaceuticals,astrazeneca,pfizer
['bcsm', 'soft trial']
biology of hr+her2- bc in very young women is different (vs &gt;40 yrs): lumb/non-luminal pam50 subtypes; ror high tumors ror high does not predict benefit from ofs (are these not so endocrine sensitive tumors?)
great analysis from soft trial
#asco2023 #asco23 #bcsm 
MD, Medical Oncologist and Clinical/Translational Researcher